EGFR and non-small cell lung carcinoma: Previous data suggested that ICI monotherapy showed limited benefit, but the combination of ICI therapy with chemotherapy had a promising effect in patients with EGFR-mutant non-small-cell lung cancer (NSCLC).21 22 In the current study, patients with ERBB3 mutations had a significantly decreased response to ICI combination therapy, with a trend toward poor PFS and OS in patients with genetic alterations in the ErbB family (online supplemental figure 9).